Integrated Advisors Network LLC Sells 223 Shares of Becton, Dickinson and Company (NYSE:BDX)

Posted by Defense World Staff on Aug 10th, 2023

Integrated Advisors Network LLC decreased its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 12.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,573 shares of the medical instruments supplier’s stock after selling 223 shares during the period. Integrated Advisors Network LLC’s holdings in Becton, Dickinson and Company were worth $389,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Biltmore Wealth Management LLC purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth $464,988,000. Red Tortoise LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $25,000. Heritage Wealth Management LLC lifted its stake in shares of Becton, Dickinson and Company by 152.4% in the 4th quarter. Heritage Wealth Management LLC now owns 106 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 64 shares during the period. Glass Jacobson Investment Advisors llc purchased a new position in shares of Becton, Dickinson and Company in the fourth quarter worth approximately $35,000. Finally, New England Capital Financial Advisors LLC bought a new stake in Becton, Dickinson and Company during the fourth quarter valued at approximately $37,000. 85.57% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Up 0.2 %

BDX stock opened at $281.53 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.25 and a quick ratio of 0.73. The company has a market capitalization of $81.67 billion, a PE ratio of 51.09, a P/E/G ratio of 2.23 and a beta of 0.57. The firm’s 50-day moving average is $262.51 and its 200 day moving average is $252.49. Becton, Dickinson and Company has a 12 month low of $215.90 and a 12 month high of $287.32.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.96 EPS for the quarter, topping the consensus estimate of $2.89 by $0.07. Becton, Dickinson and Company had a return on equity of 13.24% and a net margin of 8.73%. The company had revenue of $4.88 billion for the quarter, compared to the consensus estimate of $4.84 billion. During the same period last year, the business posted $2.66 EPS. Becton, Dickinson and Company’s quarterly revenue was up 5.1% on a year-over-year basis. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.22 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a dividend of $0.91 per share. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 66.06%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on BDX shares. Piper Sandler upped their price objective on Becton, Dickinson and Company from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, July 24th. Barclays boosted their price objective on Becton, Dickinson and Company from $284.00 to $303.00 and gave the company an “overweight” rating in a research note on Monday. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 5th. Raymond James decreased their price objective on shares of Becton, Dickinson and Company from $305.00 to $304.00 and set an “outperform” rating on the stock in a research report on Friday, August 4th. Finally, Morgan Stanley increased their price target on Becton, Dickinson and Company from $295.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, August 4th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $284.89.

Get Our Latest Stock Report on Becton, Dickinson and Company

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,300 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $277.13, for a total transaction of $360,269.00. Following the transaction, the executive vice president now owns 5,157 shares in the company, valued at $1,429,159.41. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.